trends and challenges in large scale vaccine production in high
TRANSCRIPT
![Page 1: Trends and Challenges in Large Scale Vaccine Production in High](https://reader031.vdocuments.mx/reader031/viewer/2022012919/589d754a1a28abdb498b9112/html5/thumbnails/1.jpg)
Trends and Challenges in Large Scale Vaccine Production
in High Containment Environment Senior Process Consultant, Karin Hedebo Wassard &
Senior Process Architect, Henriette Schubert
55th ABSA Conference 2012 Orlando, Florida
![Page 2: Trends and Challenges in Large Scale Vaccine Production in High](https://reader031.vdocuments.mx/reader031/viewer/2022012919/589d754a1a28abdb498b9112/html5/thumbnails/2.jpg)
Presentation Overview
• Industry & Technology trends in Vaccine production
• Challenges
• “Generic” Facility Design examples • XX • Summary & Conclusions
How to Manage Conflicting Agendas with Vaccine Facility and GMP Design in high containment when using Single Use technology?
ABSA Orlando 2012 / Karin Hedebo Wassard + Henriette Schubert 2
![Page 3: Trends and Challenges in Large Scale Vaccine Production in High](https://reader031.vdocuments.mx/reader031/viewer/2022012919/589d754a1a28abdb498b9112/html5/thumbnails/3.jpg)
Industry & Technology Trends
Upstream manufacturing suite with 100% mobile, single-use and ready-to-use manufacturing equipment - the modular design of Rentschler's new production facility was awarded the 2012 Facility of the Year Award. (Picture: Rentschler)
ABSA Orlando 2012 / Karin Hedebo Wassard + Henriette Schubert 3 http://www.process-worldwide.com/engineering_construction/plant_design/sterile_and_clean_room_technology/articles/346233/
![Page 4: Trends and Challenges in Large Scale Vaccine Production in High](https://reader031.vdocuments.mx/reader031/viewer/2022012919/589d754a1a28abdb498b9112/html5/thumbnails/4.jpg)
Vaccine manufacturing – technology trends Pilot, launch and production scale
• Multi-product facilities – moving towards high containment
• Increasing recombinant products
• Modular approach – effective facility structures
• Enabling technologies for faster production
• Acceptance of single-use technologies
• Reduction of logistic/support functions – focus on the core process
ABSA Orlando 2012 / Karin Hedebo Wassard + Henriette Schubert 4
![Page 5: Trends and Challenges in Large Scale Vaccine Production in High](https://reader031.vdocuments.mx/reader031/viewer/2022012919/589d754a1a28abdb498b9112/html5/thumbnails/5.jpg)
Vaccine facilities - Design Drivers
• Biological containment (BSL1, BSL2, BSL3, BSL4) • Minimize risk for cross contamination (GMP requirements)
• Controlling Quality • Fast-track requests / Manufacturing flexibility
• Adaptability to changes in the market / products /
Efficient pandemic solutions (vaccines)
• Controlling investment costs /Time to market ABSA Orlando 2012 / Karin Hedebo Wassard + Henriette Schubert 5
![Page 6: Trends and Challenges in Large Scale Vaccine Production in High](https://reader031.vdocuments.mx/reader031/viewer/2022012919/589d754a1a28abdb498b9112/html5/thumbnails/6.jpg)
ABSA Orlando 2012 / Karin Hedebo Wassard + Henriette Schubert 6
Single Use Technology
![Page 7: Trends and Challenges in Large Scale Vaccine Production in High](https://reader031.vdocuments.mx/reader031/viewer/2022012919/589d754a1a28abdb498b9112/html5/thumbnails/7.jpg)
From Stainless Steel towards Single Use
ABSA Orlando 2012 / Karin Hedebo Wassard + Henriette Schubert 7
http://www.sartorius.com/en/products/bioprocess/single-use-bioprocess-bags/
![Page 8: Trends and Challenges in Large Scale Vaccine Production in High](https://reader031.vdocuments.mx/reader031/viewer/2022012919/589d754a1a28abdb498b9112/html5/thumbnails/8.jpg)
Single Use technology is not a new thing & Size really matters……! • Single use technology has been known and used for many
years - mostly in smaller scale
• Now single use technology is used more frequently at large scale –1000+ liter bags!
ABSA Orlando 2012 / Karin Hedebo Wassard + Henriette Schubert 8
http://ww
w.sartorius.com
/en/products/bioreactors-fermentors/single-use/biostat-str/
![Page 9: Trends and Challenges in Large Scale Vaccine Production in High](https://reader031.vdocuments.mx/reader031/viewer/2022012919/589d754a1a28abdb498b9112/html5/thumbnails/9.jpg)
Challenges
ABSA Orlando 2012 / Karin Hedebo Wassard + Henriette Schubert 9
![Page 10: Trends and Challenges in Large Scale Vaccine Production in High](https://reader031.vdocuments.mx/reader031/viewer/2022012919/589d754a1a28abdb498b9112/html5/thumbnails/10.jpg)
Conflicting agendas & Challenges
• GMP vs Biocontainment (high containment)
• Waste management
• Primary barrier integrity
• Multiproduct (flexibility / Biorisk)
• Open knowledge sharing / Sparring
• Authorities – experience with SU in high containment
ABSA Orlando 2012 / Karin Hedebo Wassard + Henriette Schubert 10
![Page 11: Trends and Challenges in Large Scale Vaccine Production in High](https://reader031.vdocuments.mx/reader031/viewer/2022012919/589d754a1a28abdb498b9112/html5/thumbnails/11.jpg)
Conflicting agendas GMP & Biosafety
KEEP OUT KEEP IN
Bio safety GMP
ABSA Orlando 2012 / Karin Hedebo Wassard + Henriette Schubert 11
![Page 12: Trends and Challenges in Large Scale Vaccine Production in High](https://reader031.vdocuments.mx/reader031/viewer/2022012919/589d754a1a28abdb498b9112/html5/thumbnails/12.jpg)
Bio safety GMP
ABSA Orlando 2012 / Karin Hedebo Wassard + Henriette Schubert 12
Conflicting agendas GMP VS Biosafety
![Page 13: Trends and Challenges in Large Scale Vaccine Production in High](https://reader031.vdocuments.mx/reader031/viewer/2022012919/589d754a1a28abdb498b9112/html5/thumbnails/13.jpg)
Bio safety GMP
ABSA Orlando 2012 / Karin Hedebo Wassard + Henriette Schubert 13
At low biorisk – GMP normally takes precedence
At higher biorisk – Biosafety should take precedence
Conflicting agendas GMP VS Biosafety
![Page 14: Trends and Challenges in Large Scale Vaccine Production in High](https://reader031.vdocuments.mx/reader031/viewer/2022012919/589d754a1a28abdb498b9112/html5/thumbnails/14.jpg)
Solid waste handling challenges
ABSA Orlando 2012 / Karin Hedebo Wassard + Henriette Schubert 14
Objective:
• Ensure full inactivation of SU systems
• Use process that can be approved and validated
=>
• Incineration
• Autoclaving
• Reverse polymerisation (limited experience,
new technolgy / looks promising for this)
![Page 15: Trends and Challenges in Large Scale Vaccine Production in High](https://reader031.vdocuments.mx/reader031/viewer/2022012919/589d754a1a28abdb498b9112/html5/thumbnails/15.jpg)
Integrity of Single Use systems • Main risk with SU is
leaks
• Transport and handling can induce leaks
• In-situ integrity testing has long been sought for ensurence of sterility (product safety)
• Will increase safety for staff too
ABSA Orlando 2012 / Karin Hedebo Wassard + Henriette Schubert 15
![Page 16: Trends and Challenges in Large Scale Vaccine Production in High](https://reader031.vdocuments.mx/reader031/viewer/2022012919/589d754a1a28abdb498b9112/html5/thumbnails/16.jpg)
ABSA Orlando 2012 / Karin Hedebo Wassard + Henriette Schubert 16
Sterile air Integrity Testing – directly before use @ user
Integrity testing of Single Use systems
http://www.atmi.com/lifesciences/products/bpv/hit.html
http://advancedscientifics.com/lifesciences/insite-inflation-and-integrity-test-system
Helium Integrity Testing (HIT™) @ ATMI
![Page 17: Trends and Challenges in Large Scale Vaccine Production in High](https://reader031.vdocuments.mx/reader031/viewer/2022012919/589d754a1a28abdb498b9112/html5/thumbnails/17.jpg)
Challenges Biorisk & Barrier considerations
Up to 2000 L
Spill from SU equipment Aerosol generation
Event: Large Spill / leak from SU bag
ABSA Orlando 2012 / Karin Hedebo Wassard + Henriette Schubert 17
Change of primary barrier....
![Page 18: Trends and Challenges in Large Scale Vaccine Production in High](https://reader031.vdocuments.mx/reader031/viewer/2022012919/589d754a1a28abdb498b9112/html5/thumbnails/18.jpg)
Removing complexities
• Cleaning flow of equipment is minimized
• Lower cross contamination risk (batch/product)
• Faster start up of production (plug & play)
• Low start up cost
• Facilitates multi product manufacturing
• Fast batch change over
Adds to complexities
• Validation of waste inactivation of SU equipment
• Solid waste flow and quantity is increased
• Increase of raw material complexity (logistics)
• Spill handling / Spill risk
• Process room may have to act as primary barrier (spills)
• Large volume in plastic bags
ABSA Orlando 2012 / Karin Hedebo Wassard + Henriette Schubert 18
Large Scale Vaccine production Effects of single use technology
![Page 19: Trends and Challenges in Large Scale Vaccine Production in High](https://reader031.vdocuments.mx/reader031/viewer/2022012919/589d754a1a28abdb498b9112/html5/thumbnails/19.jpg)
“Generic” Facility Design Examples
ABSA Orlando 2012 / Karin Hedebo Wassard + Henriette Schubert 19
![Page 20: Trends and Challenges in Large Scale Vaccine Production in High](https://reader031.vdocuments.mx/reader031/viewer/2022012919/589d754a1a28abdb498b9112/html5/thumbnails/20.jpg)
1
2 3 4 5 6
The modular approach / “generic” facility
ABSA Orlando 2012 / Karin Hedebo Wassard + Henriette Schubert 20
• No tailor-made process rooms • Generic facility Design supports
design drivers for Multiproduct abilities and flexibility, etc.
© 2012 NNE Pharmaplan A/S
![Page 21: Trends and Challenges in Large Scale Vaccine Production in High](https://reader031.vdocuments.mx/reader031/viewer/2022012919/589d754a1a28abdb498b9112/html5/thumbnails/21.jpg)
Dance floor ..... Process Design
ABSA Orlando 2012 / Karin Hedebo Wassard + Henriette Schubert 21
PRODUCT A PRODUCT B
![Page 22: Trends and Challenges in Large Scale Vaccine Production in High](https://reader031.vdocuments.mx/reader031/viewer/2022012919/589d754a1a28abdb498b9112/html5/thumbnails/22.jpg)
Dance floor ..... Process Design
ABSA Orlando 2012 / Karin Hedebo Wassard + Henriette Schubert 22
PRODUCT A PRODUCT B
![Page 23: Trends and Challenges in Large Scale Vaccine Production in High](https://reader031.vdocuments.mx/reader031/viewer/2022012919/589d754a1a28abdb498b9112/html5/thumbnails/23.jpg)
3D views of concept facility – high containment
ABSA Orlando 2012 / Karin Hedebo Wassard + Henriette Schubert 23
© 2
012
NN
E Ph
arm
apla
n A/
S
![Page 24: Trends and Challenges in Large Scale Vaccine Production in High](https://reader031.vdocuments.mx/reader031/viewer/2022012919/589d754a1a28abdb498b9112/html5/thumbnails/24.jpg)
3D views of concept facility – high containment
ABSA Orlando 2012 / Karin Hedebo Wassard + Henriette Schubert 24
© 2
012
NN
E Ph
arm
apla
n A/
S
![Page 25: Trends and Challenges in Large Scale Vaccine Production in High](https://reader031.vdocuments.mx/reader031/viewer/2022012919/589d754a1a28abdb498b9112/html5/thumbnails/25.jpg)
3D views of concept facility – high containment
ABSA Orlando 2012 / Karin Hedebo Wassard + Henriette Schubert 25
© 2
012
NN
E Ph
arm
apla
n A/
S
![Page 26: Trends and Challenges in Large Scale Vaccine Production in High](https://reader031.vdocuments.mx/reader031/viewer/2022012919/589d754a1a28abdb498b9112/html5/thumbnails/26.jpg)
Summary & Conclusions
ABSA Orlando 2012 / Karin Hedebo Wassard + Henriette Schubert 26
![Page 27: Trends and Challenges in Large Scale Vaccine Production in High](https://reader031.vdocuments.mx/reader031/viewer/2022012919/589d754a1a28abdb498b9112/html5/thumbnails/27.jpg)
In Conclusion
• Single use technology results in less complexities
related to production and GMP processes but adds to more complexities related to Biorisk
• Large volume single use technology in high containment facilities may result in process rooms that will have to be designed as the primary barrier to mitigate biorisk
• The pharmaceutical industry should embrace more open knowledge sharing related to Biorisk discussions in high containment facilities
SU technology can be used in high containment
facilities Biorisk must be
evaluated carefully
ABSA Orlando 2012 / Karin Hedebo Wassard + Henriette Schubert 27
BUT
![Page 28: Trends and Challenges in Large Scale Vaccine Production in High](https://reader031.vdocuments.mx/reader031/viewer/2022012919/589d754a1a28abdb498b9112/html5/thumbnails/28.jpg)
Thank you for your attention! Contact details: Senior Process Specialist Ph.D. Karin Hedebo Wassard NNE Pharmaplan, Copenhagen Denmark [email protected] Mobile phone: +45 3079 39 96 Senior Process Architect Henriette Schubert NNE Pharmaplan, Copenhagen Denmark [email protected] Mobile phone: +45 3079 42 93
ABSA Orlando 2012 / Karin Hedebo Wassard + Henriette Schubert 28